Antibody-drug conjugates : fundamentals, drug development, and clinical outcomes to target cancer /
Saved in:
| Other Authors: | , |
|---|---|
| Format: | Electronic eBook |
| Language: | English |
| Published: |
Hoboken, New Jersey :
John Wiley & Sons, Incorporated,
[2017]
|
| Subjects: | |
| Online Access: | An electronic book accessible through the World Wide Web; click to view |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000nam a2200000 i 4500 | ||
|---|---|---|---|
| 001 | ebr11300198 | ||
| 003 | MiAaPQ | ||
| 006 | m o d | | ||
| 007 | cr cn||||||||| | ||
| 008 | 160715t20172017njua ob 001 0 eng|d | ||
| 020 | |z 9781119060680 (cloth) | ||
| 020 | |z 9781119060680 | ||
| 020 | |a 9781119060802 (e-book) | ||
| 040 | |a MiAaPQ |b eng |e rda |e pn |c MiAaPQ |d MiAaPQ | ||
| 050 | 4 | |a RS431.A64 |b A58 2017eb | |
| 082 | 0 | 4 | |a 615.7/98 |2 23 |
| 130 | 0 | |a Antibody-drug conjugates (Olivier) | |
| 245 | 1 | 0 | |a Antibody-drug conjugates : |b fundamentals, drug development, and clinical outcomes to target cancer / |c edited by Kenneth J. Olivier Jr. and Sara A. Hurvitz. |
| 264 | 1 | |a Hoboken, New Jersey : |b John Wiley & Sons, Incorporated, |c [2017] | |
| 264 | 4 | |c �2017 | |
| 300 | |a 1 online resource (566 pages) : |b color illustrations | ||
| 336 | |a text |2 rdacontent | ||
| 337 | |a computer |2 rdamedia | ||
| 338 | |a online resource |2 rdacarrier | ||
| 504 | |a Includes bibliographical references and index. | ||
| 505 | 0 | |a Typical antibody-drug conjugates / John Lambert -- Selecting optimal ADC targets using indication-dependent or indication-independent approaches / Robert Hollingsworth and Jay Harper -- Antibody drug conjugates : an overview of the CMC and characterization process / Janet Wolfe and Phillip Ross -- Linker and conjugation technology and improvements / Riley Ennis and Sourav Sinha -- Formulation and stability / Kouhei Tsumoto, Anthony Young, and Satoshi Ohtake -- QC assay development / Xiao-Hong Chen and Mate Tolnay -- Occupational health and safety aspects of ADCs and their toxic payloads / Robert Sussman and John Farris -- Bioanalytical strategies enabling successful ADC translation / Xiaogang Han, Lindsay King, and Steve Hansel -- Nonclinical pharmacology and mechanistic modeling of antibody drug conjugates in support of human clinical trials / Brian J. Schmidt, Chin Pan, Heather E. Vezina, Huadong Sun, Douglas D. Leipold, and Manish Gupta -- Pharmacokinetics of antibody-drug conjugates / Amrita Kamath -- Path to market approval : regulatory perspective of ADC nonclinical safety assessments / Stacey Ricci and Natalie Simpson -- Antibody drug conjugates : clinical strategies and applications / Heather E. Vezina, Lucy Lee, Brian J. Schmidt, Manish Gupta -- Antibody-drug conjugates (ADCs) in clinical development / Patricia LoRusso and Joseph McLaughlin -- ADCs approved for use : Trastuzumab emtansine (Kadcyla, T-DM1) in patients with previously treated HER2-positive metastatic breast cancer / Gail Lewis Phillips, Sanne de Hass, Sandhya Girish, and Ellie Guardino -- ADCs approved for use : Brentuximab Vedotin / Sven DeVos and Monica Mead -- Radioimmunotherapy / Jeffrey Wong and Savita Dandapani -- Radiolabeled antibody-based imaging in clinical oncology / Bart Hendriks and Daniel Gaddy -- Antibody-drug conjugates : the next evolution in the cure for cancer -- William C. Olson and Amy Q. Han. | |
| 588 | |a Description based on print version record. | ||
| 590 | |a Electronic reproduction. Ann Arbor, MI : ProQuest, 2016. Available via World Wide Web. Access may be limited to ProQuest affiliated libraries. | ||
| 650 | 0 | |a Antibody-toxin conjugates. | |
| 650 | 0 | |a Monoclonal antibodies. | |
| 650 | 0 | |a Antineoplastic agents. | |
| 650 | 0 | |a Tumors |x Treatment. | |
| 655 | 4 | |a Electronic books. | |
| 700 | 1 | |a Olivier, Kenneth J., |c Jr., |d 1968- |e editor. | |
| 700 | 1 | |a Hurvitz, Sara A., |d 1970- |e editor. | |
| 776 | 0 | 8 | |i Print version: |a Antibody-drug conjugates (Olivier) |t Antibody-drug conjugates : fundamentals, drug development, and clinical outcomes to target cancer. |d Hoboken, New Jersey : John Wiley & Sons, Incorporated, [2017] |z 9781119060680 |w (DNLM)101688103 |
| 797 | 2 | |a ProQuest (Firm) | |
| 856 | 4 | 0 | |u http://site.ebrary.com/lib/daystar/Doc?id=11300198 |z An electronic book accessible through the World Wide Web; click to view |
| 999 | |c 198771 |d 198771 | ||